

FORM PTO-1390 (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEYS DOCKET NUMBER 740709-493	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
				Not Yet Assigned 10/030251	
INTERNATIONAL APPLICATION NO. PCT/JP99/03719		INTERNATIONAL FILING DATE July 9, 1999		PRIORITY DATE CLAIMED None	
TITLE OF INVENTION PROCESS FOR PREPARING DIBENZOTHIAZEPINE DERIVATIVES					
APPLICANT(S) FOR DO/EO/US Katsumasa HARADA, Shigeyoshi NISHINO, Kiyotaka YOSHII					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 					
Items 11 to 20 below concern document(s) or information included:					
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
13. <input type="checkbox"/> A FIRST preliminary amendment.					
14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.					
15. <input type="checkbox"/> A substitute specification.					
16. <input type="checkbox"/> A change of power of attorney and/or address letter.					
17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.					
18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).					
19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).					
20. <input checked="" type="checkbox"/> Other items or information:					
1.) Application Data Sheet					

U.S. APPLICATION NO (If known, see 37 CFR 1.50) Not Yet Assigned 107030251		INTERNATIONAL APPLICATION NO PCT/JP99/03719		ATTORNEYS DOCKET NUMBER 740709-493	
--	--	---	--	--	--

21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(3)) paid to USPTO \$740.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS		PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<div style="font-size: 1.5em; font-weight: bold;">\$890.00</div>			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE				
Total claims	8 - 20 =	0	X \$18.00	\$ -----			
Independent claims	3 - 3 =	0	X \$84.00	\$ -----			
MULTIPLE DEPENDENT CLAIM(S) (if applicable) None			+ \$280.00	\$ -----			
TOTAL OF ABOVE CALCULATIONS =				\$890.00			
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$			
SUBTOTAL =				\$890.00			
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$			
TOTAL NATIONAL FEE =				\$890.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$40.00			
TOTAL FEES ENCLOSED =				\$930.00			
				Amount to be refunded:	\$		
				charged:	\$		

a. ☒ A check in the amount of **\$930.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 19-2380 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2380(740709-493). A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

NIXON PEABODY LLP
8180 Greensboro Drive
Suite 800
McLean, Virginia 22102

SIGNATURE

Donald R. Studebaker
 NAME

#32,815
 REGISTRATION NUMBER

 DRS/sas January 9, 2002

S P E C I F I C A T I O N


PROCESS FOR PREPARING DIBENZOTHAIAZEPINE DERIVATIVES

5

[Field of Invention]

The present invention relates to a process for preparing a dibenzothiazepine derivative of value as an intermediate compound for the preparation of pharmaceuticals. In particular, the invention relates to a process for the preparation of a dibenzothiazepine derivative of the following formula (5):

15



(5)

20

(in which each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ is the same or different from each other, and represents a hydrogen atom, an alkyl group, an alkoxy group, an alkylcarbonyl group, an aryl group, an aryloxy group, or an arylcarbonyl group, each group being optionally substituted) which is of value as an intermediate compound for preparing 11-[4-(2-(2-hydroxyethoxy)ethyl)-1-piperidinyl]-dibenzothiazepine and its derivatives, which is known to be effective as an antipsychotic pharmaceutical.

30

[Background of Invention]

EP 0282236-A1 describes that a dibenzothiazepine derivative of the above-mentioned formula (5) can be processed to give 11-[4-(2-(2-hydroxyethoxy)ethyl)-1-piperidinyl]-dibenzothiazepine derivative which is of value as an antipsychotic pharmaceutical. In more detail, dibenzo-

35

[b,f] [1,4]thiazepin-11-one, which is a representative compound of the dibenzothiazepine derivatives of the formula (5), is reacted with phosphorus oxychloride to yield a 11-chloro-dibenzothiazepine derivative; and to the 11-chloro-dibenzothiazepine derivative is added piperazine to yield a 11-piperazinyl-dibenzothiazepine derivative, which is subsequently reacted with 2-chloroethoxyethanol under basic conditions to give the desired 11-[4-(2-(2-hydroxyethoxy)ethyl)-1-piperidinyl]dibenzothiazepin.

EP 0282236-A1 further describes that the dibenzothiazepin-11-one is prepared from phenyl 2-(phenylthio)phenylcarbamate or its analogous compound by cyclization in the presence of polyphosphoric acid.

Helv. Chim. Acta., vol.42, pp.1263 (1959) describes that a dibenzothiazepine derivative can be prepared by the steps of heating a methyl thiosalicylate derivative with a 2-halogenated nitrobenzene derivative in the presence of sodium to give a 2-nitro-2'-carboxy-diphenylsulfide derivative, which is then reduced using a Raney-nickel catalyst to yield a 2-amino-2'-carboxy-diphenylsulfide derivative, which is finally heated to give a dibenzothiazepine derivative.

Org. Prep. Proced. Int., pp. 287 (1974) describes that a dibenzothiazepine derivative can be prepared by the steps of heating a thiosalicylic acid ester derivative and 2-iodo-nitrobenzene derivative in the presence of sodium methylate and copper, treating the resulting compound successively with an alkaline solution and an acidic solution to give a 2-nitro-2'-carboxy-diphenylsulfide derivative, reducing the derivative by ferrous sulfate in an aqueous ammonia solution to give a 2-amino-2'-carboxy-diphenylsulfide derivative, and heating the resulting derivative under reduced pressure.

WO 92/19607 describes that a dibenzothiazepine derivative of the formula (5) can be prepared by the steps

of reacting 2-aminothiophenol with 2-fluorobenzonitrile to give 2-(2-aminophenylthio)benzonitrile, hydrolyzing the resultant to give 2-(2-carboxyphenylthio)aniline, and finally cyclizing the aniline derivative.


As described above, various processes for preparing a dibenzothiazepine derivative of the formula (5) are known. However, the known preparing processes have various disadvantageous features such as a low yield, high temperature reaction conditions, use of starting compounds which are not easily available, and/or complicated post treatment. These disadvantageous features are naturally unfavorable in the industrial preparation of the desired dibenzothiazepine derivative.

[Disclosure of Invention]

It is an object of the present invention to provide a process for industrially preparing a dibenzothiazepine derivative of the formula (5), that is, a process for preparing a dibenzothiazepine derivative in a good yield without complicated post treatment, employing easily available material.

As the result of the earnest study of the present inventors, they have found a novel process for preparing a dibenzothiazepine derivative of the formula (5) in a good yield with easy operation by employing an easily available nitrobenzene derivative as well as an easily available thiosalicylic acid derivative.


The invention resides in a process for preparing a dibenzothiazepine derivative of the following formula (5):




(5)

in which each of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 independently represents a hydrogen atom, an alkyl group, an alkoxy group, an alkylcarbonyl group, an aryl group, an aryloxy group, or an arylcarbonyl group, each group being optionally substituted,
which comprises the steps of:


reacting a nitrobenzene derivative of the following formula (1):



in which each of R^1 , R^2 , R^3 and R^4 has the meaning as described above, and X represents a halogen atom,
with a thiosalicylic acid derivative of the following formula (2):




in which each of R^5 , R^6 , R^7 and R^8 has the meaning as described above,
to obtain a 2-nitro-2'-carboxy-diphenylsulfide derivative of the following formula (3):



in which each of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 has the meaning as described above;

reducing the obtained 2-nitro-2'-carboxy-diphenyl-sulfide derivative to obtain a 2-amino-2'-carboxy-diphenylsulfide derivative of the following formula (4):




in which each of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 has the meaning as described above;

and

subjecting the obtained 2-amino-2'-carboxy-diphenyl-sulfide derivative to dehydration-condensation reaction.


The invention further resides in a process for preparing a dibenzothiazepine derivative of the formula (5):




in which each of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 has the meaning as described above,

which comprises the steps of:

reducing a 2-nitro-2'-carboxy-diphenylsulfide derivative of the following formula (3):



in which each of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 independently represents a hydrogen atom, an alkyl group, an alkoxy group, an alkylcarbonyl group, an aryl group, an aryloxy group, or an arylcarbonyl group, each group being optionally substituted,
to obtain a 2-amino-2'-carboxy-diphenylsulfide derivative of the following formula (4):







in which each of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 has the meaning as described above;

and

subjecting the obtained 2-amino-2'-carboxy-diphenylsulfide derivative to dehydration-condensation reaction.

The present invention further resides in a 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3).

The steps of the process for preparing a dibenzothiazepine derivative of the formula (5) according to the invention is illustrated by the following scheme:



[Preferred Embodiments of Invention]

In the formulas of the compounds involved in the process of the invention, "an alkyl group possibly having substituent" represented by R^1 through R^8 means a straight chain or branched chain alkyl group of 1 to 10 carbon atoms having no substituent, or a straight chain or branched chain alkyl group of 1 to 10 carbon atoms having substituent.

The above "straight chain or branched chain alkyl group of 1 to 10 carbon atoms having no substituent" preferably is a straight chain or branched chain alkyl group having 1 to 8 carbon atoms, more preferably 1 to 5 carbon atoms. Examples of the alkyl groups include methyl, ethyl, propyl (including isomers), butyl (including isomers), pentyl (including isomers), hexyl (including isomers), heptyl (including isomers), octyl (including isomers), nonyl (including isomers), and decyl (including isomers). Preferred are methyl, ethyl, propyl (including isomers), butyl (including isomers), pentyl (including isomers), hexyl (including isomers), heptyl (including isomers), and octyl (including isomers). Most preferred are methyl, ethyl, propyl (including isomers), butyl (including isomers), and pentyl (including isomers).

Examples of the alkyl moiety of the above "straight chain or branched chain alkyl group of 1 to 10 carbon atoms having substituent" include alkyl groups described in the above formula (1).

The substituent of the above-mentioned "straight chain or branched chain alkyl group of 1 to 10 carbon atoms having substituent" may be attached to any position of the alkyl moiety. Examples of the substituents include straight chain or branched chain alkoxy groups having 1 to 10 carbon atoms such as methoxy, ethoxy, propoxy (including isomers), butoxy (including isomers), pentyloxy (including isomers), hexyloxy (including isomers), heptyloxy (including isomers), octyloxy (including isomers), and decyloxy (including isomers).

isomers), nonyloxy (including isomers), and decyloxy (including isomers); alkylcarbonyl groups which has 2 to 6 carbon atoms and contains a straight chain or branched chain alkyl group having 1 to 5 carbon atoms, such as
5 acetyl, propionyl (including isomers), butanoyl (including isomers) and pentanoyl (including isomer); phenylcarbonyl groups which may have substituent; and phenyl which may have substituent.

The "phenylcarbonyl group which may be substituted"
10 means a phenylcarbonyl group having no substituent or phenylcarbonyl group having substituent. The "phenyl group which may be substituted" means phenyl group having no substituent or phenyl group having substituent. The substituent for the phenylcarbonyl group and phenyl group
15 may be phenyl, phenylcarbonyl, one of the above-mentioned alkyl, alkoxy, and alkylcarbonyl groups.

In the invention, the "alkoxy group possibly having substituent" represented by R^1 through R^8 of the formulas (2), (3), (4) and (5) means an alkoxy group having 1 to
20 10 carbon atoms and containing a straight chain or branched chain alkyl moiety which has no substituent and has 1 to 10 carbon atoms, or an alkoxy group having 1 to 10 carbon atoms and containing a straight chain or branched chain alkyl moiety which has substituent and has
25 1 to 10 carbon atoms.

Examples of the "alkoxy group having 1 to 10 carbon atoms and containing a straight chain or branched chain alkyl moiety which has no substituent and has 1 to 10 carbon atoms" include those described above. Examples of
30 the "alkoxy group having 1 to 10 carbon atoms and containing a straight chain or branched chain alkyl moiety which has a substituent and has 1 to 10 carbon atoms" include the above-mentioned alkyl groups, an alkylcarbonyl group having 2 to 6 carbon atoms, a phenylcarbonyl
35 group which may have substituent and phenyl which may have substituent.

The "alkylcarbonyl group possibly having substituent" for R^1 through R^8 in each formula in the process of dibenzothiazepine derivative according to the invention means an alkylcarbonyl group having 2 to 11 carbon atoms and containing a straight chain or branched chain alkyl moiety which has no substituent and has 1 to 10 carbon atoms, or an alkylcarbonyl group having 2 to 11 carbon atoms and containing a straight chain or branched chain alkyl moiety which has substituent and has 1 to 10 carbon atoms.

Examples of the alkyl moieties of "alkylcarbonyl group having 2 to 11 carbon atoms and containing a straight chain or branched chain alkyl moiety which has no substituent and has 1 to 10 carbon atoms" include those described above. Examples of the substituents of "alkylcarbonyl group having 2 to 11 carbon atoms and containing a straight chain or branched chain alkyl moiety which has substituent and has 1 to 10 carbon atoms" include those described above.

The "aryl group possibly having substituent" for R^1 through R^8 in each formula in the process of preparation of a dibenzothiazepine derivative according to the invention means an aryl group having no substituent or aryl group having substituent.

Examples of the "aryl group having no substituent" include phenyl, naphthyl and anthoryl. Preferred are phenyl and naphthyl. Most preferred is phenyl. Examples of substituents of the "aryl group having a substituent" include those described above for the alkyl groups.

The "aryloxy group possibly having substituent" for R^1 through R^8 in each formula in the process for preparing a dibenzothiazepine derivative according to the invention means an aryloxy group having an aryl moiety having no substituent or an aryloxy group having an aryl moiety having substituent.

Examples of the aryl groups of "aryloxy group having

aryl moiety having no substituent" include aryl groups described above. Examples of substituents of "aryloxy group having aryl moiety having a substituent" include substituents described above for the alkyl group.

5 The "arylcarbonyl group possibly having substituent" for R^1 through R^8 in each formula in the process for preparing a dibenzothiazepine derivative according to the invention means an arylcarbonyl group having an aryl moiety having no substituent, or an arylcarbonyl group having an aryl moiety having a substituent.

10 Examples of the aryl groups of "arylcarbonyl group having aryl moiety having no substituent" include the aryl groups described above. Examples of the substituents of "arylcarbonyl group having aryl moiety having substituent" include the substituents described above for the alkyl group.

15 The groups of R^1 through R^8 may be the same or different from each other, and each preferably is a hydrogen atom, an alkyl group, an alkoxy group, an alkylcarbonyl group, an aryl group, an aryloxy group, or an arylcarbonyl group. Most preferred are a hydrogen atom, an alkyl group, an alkoxy group, and an alkylcarbonyl group.

20 The halogen atom for X of the formula (1) can be fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine, and bromine.

25 Each of the steps of the process for preparing the dibenzothiazepine derivatives according to the invention is described hereinafter in more detail.

30 In the first step of the process for preparing the dibenzothiazepine derivatives of the invention, a nitrobenzene derivative of the formula (1) and a thiosalicylic acid derivative of the formula (2) are reacted in a solvent, preferably in the presence of a base, to prepare a 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3).

35 Examples of the nitrobenzene derivatives of the for-

mula (1) employed in the first step include 2-chloro-nitrobenzene, 2-bromonitrobenzene, 2-fluoronitrobenzene, 2-iodonitrobenzene, 2-chloro-5-methoxy-nitrobenzene, 2-bromo-5-methoxy-nitrobenzene, 2-fluoro-5-methoxy-nitrobenzene, 2-iodo-5-methoxy-nitrobenzene, 2-chloro-5-methyl-nitrobenzene, 2-bromo-5-methyl-nitrobenzene, 2-fluoro-5-methyl-nitrobenzene, 2-iodo-5-methyl-nitrobenzene, 2-chloro-5-phenyl-nitrobenzene, 2-bromo-5-phenyl-nitrobenzene, 2-fluoro-5-phenyl-nitrobenzene, 2-iodo-5-phenyl-nitrobenzene, 2-chloro-5-acetyl-nitrobenzene, 2-bromo-5-acetyl-nitrobenzene, 2-fluoro-5-acetyl-nitrobenzene, and 2-iodo-5-acetyl-nitrobenzene. Preferred are 2-chloro-nitrobenzene and 2-bromonitrobenzene.

Examples of the thiosalicylic acid derivatives of the formula (2) employed in the first step include thiosalicylic acid, 5-methoxy-thiosalicylic acid, 5-methyl-thiosalicylic acid, 5-phenyl-thiosalicylic acid, and 5-acetyl-thiosalicylic acid. Preferred are thiosalicylic acid and 5-methoxythiosalicylic acid.

The nitrobenzene derivative of the formula (1) is generally employed in an amount of 0.7 to 10 mol., preferably 1.0 to 5 mol., per one mol. of the thiosalicylic acid of the formula (2).

The above-mentioned first step is generally performed in a solvent. There are no specific limitations on the solvents, so long as the solvents do not participate in the reaction. Examples of the solvents include water; amide solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone and dimethylimidazolidone; aliphatic alcohols such as methanol, ethanol, n-propanol, isopropanol and n-butanol; ketones such as acetone, methyl ethyl ketone and methyl isobutyl ketone; and nitriles such as acetonitrile and benzonitrile. Preferred are water, amides and aliphatic alcohols.

The solvent in the first step is preferably employed in such manner that a weight ratio of the amount of the

nitrobenzene of the formula (1) against the amount of the solvent is in the range of 0.05 to 1.0, more preferably 0.1 to 0.8.

5 The reaction of the first step is generally performed at a temperature of not higher than the boiling temperature of the solvent employed, preferably at a temperature of 0 to 150°C, more preferably 20 to 100°C. The reaction period of the first step greatly depends on the reaction temperature, but the reaction is generally
10 complete within 20 hours.

20030251 010902
15 The reaction of the first step is generally performed in the presence of a base. Examples of the preferred bases include potassium carbonate, sodium carbonate, lithium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, and sodium methylate. Most preferred are potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, and sodium methylate. The base is generally employed in an amount corresponding to 1 to 10 moles, preferably 1.5 to 5 moles.,
20 per one mole of the total amounts of the starting compounds.

In the reaction of the first step, additives for accelerating the reaction other than the base can be added. Examples of the additives include potassium iodide and N,N-dimethylaminopyridine. The additive can be
25 employed in an amount of 0.0005 to 0.5 mol. (mol of additive/mol of nitrobenzene derivative), preferably 0.001 to 0.1 mol., per one mole of the nitrobenzene derivative of the formula (1).

30 The chemical structure of the 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3) obtained in the first step of the invention depends on the chemical structure of the nitrobenzene derivative of the formula (1) as well as on the chemical structure of the thiosalicylic acid derivative of the formula (2). Examples of
35 the 2-nitro-2'-carboxy-diphenylsulfide derivatives in-

clude 2-nitro-2'-carboxy-diphenylsulfide, 2-nitro-4-methoxy-2'-carboxy-diphenylsulfide, 2-nitro-4-methyl-2'-carboxy-diphenylsulfide, 2-nitro-4-phenyl-2'-carboxy-diphenylsulfide, 2-nitro-4-acetyl-2'-carboxy-diphenylsulfide, and 2-nitro-2'-carboxy-4'-methoxy-diphenylsulfide. Preferred are 2-nitro-2'-carboxy-diphenylsulfide and 2-nitro-2'-carboxy-4'-methoxy-diphenylsulfide.

The 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3) prepared in the first step can be recovered by a combination of a conventional washing procedure and a conventional separating procedure, such as a combination of addition of an acid to make the reaction mixture acidic and filtration of the precipitated crystalline product to obtain a crude product, or a combination of addition of water and an extracting solvent (organic solvent) to the reaction mixture and addition of an acid to make the aqueous phase of the reaction mixture acidic. Otherwise, the crude product can be recovered by placing the organic solvent portion under reduced pressure. Thus obtained crude product *per se* can be employed in the next step. The crude product can be further purified, if necessary, by column chromatography or recrystallization. The process for purification can be selected depending on each compound to be purified. The acid preferably employed is hydrochloric acid, sulfuric acid, phosphoric acid, or acetic acid.

In the second step of the process of the invention, the 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3) is reduced to give a 2-amino-2'-carboxy-diphenylsulfide derivative of the formula (4).

The reduction procedure performed in the second step is not limited, and known procedures for reducing the nitro group can be employed. Preferred are Raney-nickel method (hereinafter referred to as reaction (A)), ferrous salt method (hereinafter referred to as reaction (B)) and a method employing palladium, platinum or its compounds

(hereinafter referred to as reaction (C)). In reduction procedure, hydrogen gas is employed as supply source of hydrogen.

5 Reaction (A): Raney-nickel Method

10 Raney-nickel can be employed in the method in an amount of 1.0 to 80 wt.% (in terms of nickel), preferably 5.0 to 40 wt.%, per the amount of the 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3). Examples of Raney-nickels employable in the reaction include 10-60% Ni-Al alloy and that containing Cr and Mo. Stabi-
15 lized nickel can be also employed. The yield is not greatly influenced by the developing method of Raney-nickel. Known W-6 method ("Raney Catalyst" pp. 55. by Kubomatsu Teruo and Komatsu Shinichiro, issued by Kawaken
20 Finechemical, Co., Ltd., May 10, 1971) brought about most favorable results. Other developing methods can be sufficiently effective. In the case of using the Raney-nickel method, the reaction is generally performed in the presence of hydrogen gas under pressure. Accordingly,
25 the reaction is generally performed in an autoclave. The hydrogen gas pressure preferably is as high as possible. Generally, the hydrogen gas pressure is in the range of 5 to 100 atm. The reaction may be performed under atmospheric pressure. In this case, the reaction is carried out in the stream of hydrogen gas.

There are no specific limitations on the solvents employed in the reaction (A), so long as the solvents do not participate in the reaction. Examples of the sol-
30 vents include aliphatic alcohols such as methanol, ethanol, n-propanol, isopropanol and n-butanol. The volume of the solvent is so selected that the volume of 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3) would be 0.05 to 0.6 volume, preferably 0.1 to 0.6 volume
35 per one volume of the solvent (volume of 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula/volume of

solvent).

The reaction (A) can be carried out at a temperature up to the boiling point of the solvent. The reaction is generally carried out at a temperature of 20 to 200°C, preferably 25 to 150°C. The reaction period depends on the temperature and hydrogen gas pressure. The reaction is usually complete within 20 hours.

After the reaction (A) is complete, the 2-amino-2'-carboxy-diphenylsulfide derivative of the formula (4) produced in the reduction can be recovered by a conventional combination of a washing procedure and a separating procedure, such as a combination of filtration of the reaction mixture and concentration of the filtrate under reduced pressure. The product obtained above *per se* can be employed in the next step. If desired, the product can be purified by column chromatography or recrystallization. The purification procedure can be selected depending on the product to be purified.

Reaction (B): Ferrous Salt Method

Examples of ferrous salts employable in the reaction include ferrous sulfate and ferrous chloride. These salts can be employed in the form of hydrate or anhydride. Preferred are ferrous sulfate 7 hydrates, ferrous salt anhydrides, ferrous salt 4 hydrates, and ferrous salt *n* hydrates. The salt can be employed in a volume of 0.1 to 30 (in terms of iron atom), preferably 0.5 to 10, per one volume of the 2-nitro-2'-carboxy-diphenylsulfide of the formula (3).

Mixture of water and aqueous ammonia is generally employed as a solvent for the reaction (B). Aqueous ammonia can be prepared by employing concentrated aqueous ammonia (ammonia concentration: 25 to 28 wt.%). Aqueous ammonia of lower concentration or water containing ammonia gas can be also employed, so long as the content of ammonia is sufficient. Water can be so employed that the

205010" 1520E001
volume of 2-nitro-2'-carboxy-diphenylsulfide derivative
of the formula (3) would be 0.01 to 0.4 equivalent per
one volume of water (volume of 2-nitro-2'-carboxy-di-
phenylsulfide derivative/volume of water), preferably
5 0.02 to 0.2 equivalent (the same as above). The volume
of ammonia is so selected that the volume of 2-nitro-2'-
carboxy-diphenylsulfide derivative would be 0.005 to 0.5
equivalent, preferably 0.01 to 0.5 equivalent, per one
volume of ammonia (volume of 2-nitro-2'-carboxy-diphenyl-
10 sulfide derivative/volume of ammonia).

The reaction (B) can be carried out at a temperature
up to the boiling point of the solvent. The reaction is
generally carried out at a temperature of 20 to 100°C,
preferably 40 to 90°C. The reaction period depends on the
15 temperature. The reaction is usually complete within 2
hours.

After the reaction (B) is complete, the 2-amino-2'-
carboxy-diphenylsulfide derivative of the formula (4)
produced in the reduction can be recovered by a conven-
20 tional combination of a washing procedure and a separat-
ing procedure. For example, the reaction mixture is fil-
tered, and an acid (e.g., hydrochloric acid, sulfuric
acid, phosphoric acid and acetic acid) is added to the
filtrate, thereby placing its pH on the acidic side. The
25 obtained filtrate is concentrated under reduced pressure
to obtain a crude compound. The product obtained above
per se can be employed in the next step. If desired, the
product can be purified by column chromatography or re-
crystallization. The purification procedure can be se-
30 lected depending on the product to be purified.

Reaction (C): Method employing palladium or platinum (or
its compounds)

The reaction can be performed in the presence of a
35 reducing catalyst (i.e., hydrogenation catalyst) selected
from the group consisting of palladium (Pd), platinum

(Pt), a palladium compound, and a platinum compound. The reducing catalyst can be deposited on a carrier such as carbon (C) or barium sulfate. Preferred are Pd/C, Pd/barium sulfate, and platinum oxide. Most preferred is Pd/C.

The reducing catalyst comprising palladium or platinum can be employed in an amount corresponding to 0.01 to 30 weight % (in terms of palladium or platinum metal), preferably 0.05 to 10 weight %, per the amount of the 2-nitro-2'-carboxy-disulfide derivative of the formula (3). If the catalyst is deposited on a carrier, the catalyst can be deposited in an amount of 1 to 10 weight % (in terms of palladium or platinum metal), per the amount of the carrier. If Pd/C is employed, a dry catalyst having a water content of not more than 5%, as well as a wet catalyst containing water component in a greater amount can be employed. The wet catalyst may contain 10 to 70 weight % (amount of water per the total amount of the catalyst and carrier).

When platinum oxide is employed in the reaction (C) as the reducing catalyst, it is preferably employed in an amount of 0.1 to 50 weight %, preferably 1 to 30 weight %, per the amount of the 2-nitro-2'-carboxy-disulfide derivative of the formula (3).

The reaction (C) is generally performed in the presence of hydrogen gas under pressure. Accordingly, the reaction is generally performed in an autoclave. The hydrogen gas pressure preferably is as high as possible. Generally, the hydrogen gas pressure is in the range of 2 to 100 atm. The reaction may be performed under atmospheric pressure. In this case, the reduction (or hydrogenation) can be carried out in the stream of hydrogen gas.

The reaction (C) is generally carried out in a solvent. There are no specific limitations on the solvent employed, so long as the solvents do not participate in

the reaction. Examples of the solvents include aliphatic alcohols such as methanol, ethanol, n-propanol, isopropanol and n-butanol, and amide solvents such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone and dimethylimidazolidone. The aliphatic alcohols are preferred. The solvent is preferably employed in an amount of 2 to 70 weight %, more preferably 5 to 50 weight %, per the amount of the 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3).

The reaction (C) is generally carried out at a temperature of 10 to 200°C, preferably 20 to 150°C. The reaction period depends on the reaction temperature and hydrogen gas pressure, but generally is not longer than 30 hours.

The 2-amino-2'-carboxy-diphenylsulfide derivative of the formula (4) produced in the reaction (C) (hydrogenation) can be recovered by a conventional combination of a washing procedure and a separating procedure, such as a combination of filtration of the reaction mixture and concentration of the filtrate under reduced pressure. The product obtained above *per se* can be employed in the next step. If desired, the product can be purified by column chromatography or recrystallization. The purifying procedure can be selected dependent on the product to be purified.

The chemical structure of the 2-amino-2'-carboxy-diphenylsulfide derivative of the formula (4) prepared in the second step (reduction step) is dependent on the chemical structure of the 2-nitro-2'-carboxy-diphenylsulfide of the formula (3) employed in the second step as the starting compound. Examples of the 2-amino-2'-carboxy-diphenylsulfide derivatives of the formula (4) include 2-amino-2'-carboxy-diphenylsulfide, 2-amino-4-methoxy-2'-carboxy-diphenylsulfide, 2-amino-4-methyl-2'-carboxy-diphenylsulfide, 2-amino-4-phenyl-2'-carboxy-diphenylsulfide, 2-amino-4-acetyl-2'-carboxy-diphenyl-

sulfide, and 2-amino-2'-carboxy-4'-methoxy-diphenylsulfide. Preferred are 2-amino-2'-carboxy-diphenylsulfide and 2-amino-2'-carboxy-4'-methoxy-diphenylsulfide.

In the third step of the invention, the 2-amino-2'-carboxy-diphenylsulfide derivative of the formula (4) is condensed by dehydration to prepare the dibenzothiazepine derivative of the formula (5).

The reaction of the third step can be performed using no solvent. However, the reaction is preferably carried out in a hydrophobic organic solvent which does not participate in the reaction. Examples of the organic solvents include aromatic hydrocarbons such as toluene, xylene, cumene, and benzene; halogenated aromatic hydrocarbons such as chlorobenzene, 1,2-dichlorobenzene, 1,3-dichlorobenzene, 1,4-dichlorobenzene, bromobenzene, 1,2-dibromobenzene, 1,3-dibromobenzene, and 1,4-dibromobenzene; cyclic aliphatic hydrocarbons such as cyclohexane, cycloheptane, and cyclooctane; and aliphatic esters such as ethyl acetate, butyl acetate, methyl butyrate, ethyl butyrate, and butyl butyrate. Preferred are toluene, xylene, cumene, and 1,2-dichlorobenzene.

There is no specific limitation on the amount of the solvent employed in the third step. However, it is preferred that the solvent is employed in an amount to give a ratio of the weight amount of the 2-amino-2'-carboxy-diphenylsulfide derivative against the volume amount of the solvent (W/V %) of not less than 3%, preferably in the range of 4 to 40%. The reaction of the third step can be carried out in a Dean-Stark apparatus for performing azeotropic dehydration (for refluxing with removal of water produced in the reaction) so as to accelerate the reaction rate and the conversion ratio. There is no specific limitation on the reaction temperature of the third step, so long as the temperature is lower than the boiling point of the solvent employed. Preferred is a temperature of 100 to 200°C.

The chemical structure of the dibenzothiazepine derivative of the formula (5) obtained in the third step depends on the chemical structure of the 2-amino-2'-carboxy-diphenylsulfide derivative of the formula (4).

5 Examples of the dibenzothiazepine derivatives of the formula (5) include dibenzo[b,f][1,4]thiazepin-11-one, 8-methyl-dibenzo[b,f][1,4]thiazepin-11-one, 8-phenyl-dibenzo[b,f][1,4]thiazepin-11-one, 8-methoxy-dibenzo[b,f][1,4]thiazepin-11-one, and 2-methoxy-dibenzo[b,f][1,4]thiazepin-11-one. Preferred are dibenzo[b,f][1,4]thiazepin-11-one and 2-methoxy-dibenzo[b,f][1,4]thiazepin-11-one.

2003051 010502
15 The dibenzothiazepine derivative of the formula (5) produced in the third step can be easily recovered by cooling the reaction mixture to precipitate a crystalline product of the dibenzothiazepine derivative. The precipitated crystalline product is then collected by filtration to give the dibenzothiazepine derivative of a high purity. If further purification is required, re-crystallization or column chromatography can be utilized. Otherwise, the reaction mixture is made alkaline by addition of an aqueous alkaline solution and then the aqueous portion is removed, in advance of precipitating the resultant product. The remaining organic portion is then
25 cooled to precipitate a crystalline product of the dibenzothiazepine derivative. The aqueous alkaline solution can be produced by the use of sodium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, or potassium hydroxide. The alkaline compound
30 in the alkaline solution preferably is at a concentration of 0.5 to 30 weight %. There is no limitation on the amount of the alkaline solution, but the alkaline solution is preferably used in an amount of 0.05 to 0.4 weight part, based on one weight part of the product of the third step (i.e., dibenzothiazepine derivative of the
35 formula (5)).

Preferred embodiments of the invention are described below.

1) The nitrobenzene derivative of the formula (1) is 2-chloronitrobenzene or 2-bromonitrobenzene.

2) The thiosalicylic acid derivative of the formula (2) is thiosalicylic acid or 5-methoxythiosalicylic acid.

3) In the first step of the process for preparation of dibenzothiazepine derivative s of the invention, a base such as potassium carbonate, sodium hydroxide, or sodium methyate is used.

4) The 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3) is 2-nitro-2'-carboxy-diphenylsulfide or 2-nitro-2'-carboxy-4'-methoxy-diphenylsulfide.

5) In the first step of the process for preparing a dibenzothiazepine derivatives of the invention, N,N-dimethylformamide or methanol is employed as a reaction solvent.

6) In the reduction of the second step of the process for preparing a dibenzothiazepine derivative of the invention, Raney-nickel is employed as the reducing agent, and methanol or n-butanol is employed as the solvent.

7) In the reduction of the second step of the process for preparing a dibenzothiazepine derivative of the invention, ferrous sulfate·hydrate is employed as the reducing agent, and aqueous ammonia solution is employed as the solvent.

8) The reduction of the second step of the process for preparing a dibenzothiazepine derivative of the invention is performed in the presence of any catalyst selected from Pd/C, Pd/barium sulfate and platinum oxide, employing methanol or ethanol as the solvent.

9) The 2-amino-2'-carboxy-diphenylsulfide derivative of the formula (4) is 2-amino-2'-carboxy-diphenylsulfide, 2-amino-2'-carboxy-4'-methoxy-diphenylsulfide or

2-methoxy-dibenzo[b,f] [1,4]thiazepin-11-one.

10) The dibenzothiazepine derivative of the formula (5) is dibenzo[b,f] [1,4]thiazepin-11-one or 2-methoxy-dibenzo[b,f] [1,4]thiazepin-11-one.

5 11) In the first step, the nitrobenzene derivative of the formula (1) is 2-chloronitrobenzene or 2-bromonitrobenzene, the thiosalicylic acid derivative of the formula (2) is thiosalicylic acid or 5-methoxythiosalicylic acid, the base is potassium carbonate, the solvent is N,N-dimethylformamide, and the resulting 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3) is 2-nitro-2'-carboxy-diphenylsulfide or 2-nitro-2'-carboxy-4'-methoxy-diphenylsulfide.

15 12) In the second step, the 2-nitro-2'-carboxy-diphenylsulfide or 2-nitro-2'-carboxy-4'-methoxy-diphenylsulfide is reduced by hydrogen gas in the presence of platinum, palladium, or its compound, to give 2-amino-2'-carboxy-diphenylsulfide or 2-amino-2'-carboxy-4'-methoxy-diphenylsulfide, respectively.

20 13) In the third step, 2-amino-2'-carboxy-diphenylsulfide or 2-amino-2'-carboxy-4'-methoxy-diphenylsulfide is converted into dibenzo[b,f] [1,4]thiazepin-11-one or 2-methoxy-dibenzo[b,f] [1,4]thiazepin-11-one, respectively.

25 The invention is further described by the following non-limiting examples.

[Example 1]

30 In 120 mL of N,N-dimethylformamide were dissolved 94.5 g (0.60 mol.) of 2-chloronitrobenzene and 159.0 g (1.15 mol.) of potassium carbonate. To the resulting N,N-dimethylformamide solution was dropwise added a solution of 77.1 g (0.50 mol.) of thiosalicylic acid in 120 mL of N,N-dimethylformamide. The resulting mixture was then stirred at 70°C for 6 hours, for carrying out the reaction. To the reaction mixture were added 800 mL of water and 700 mL of ethyl acetate. The aqueous portion

35

was separated and made acidic by addition of 400 g of ice and 194 mL of conc. hydrochloric acid. The acidic solution was stirred at room temperature for one hour. The precipitated crystalline product was collected by filtration and dried to obtain 134.0 g (0.49 mol.) of 2-nitro-2'-carboxy-diphenylsulfide as a yellow powder. The yield from thiosalicylic acid was 98%.

$^1\text{H-NMR}$ (DMSO-d_6): δ

7.1-8.3 (m, 8H), 13.1-13.5 (br., 1H)

[Example 2]

In 120 mL of N,N-dimethylformamide were dissolved 94.5 g (0.60 mol.) of 2-chloronitrobenzene and 159.0 g (1.15 mol.) of potassium carbonate. To the resulting N,N-dimethylformamide solution was dropwise added a solution of 77.1 g (0.50 mol.) of thiosalicylic acid in 120 mL of N,N-dimethylformamide. The resulting mixture was then stirred at 70°C for 6 hours, for carrying out the reaction. The aqueous portion was separated and made acidic by addition of 200 mL of water and 194 mL of conc. hydrochloric acid. The acidic solution was stirred at room temperature for one hour. The precipitated crystalline product was collected by filtration and dried to obtain 123.0 g (0.45 mol.) of 2-nitro-2'-carboxy-diphenylsulfide as a yellow powder. The yield from thiosalicylic acid was 90%.

[Example 3]

The procedures of Example 1 were repeated except for employing 121.2 g (0.60 mol.) of 2-bromonitrobenzene in place of 2-chloronitrobenzene, to obtain 134.0 g (0.49 mol.) of 2-nitro-2'-carboxy-diphenylsulfide. The yield from thiosalicylic acid was 98%.

[Example 4]

The procedures of Example 1 were repeated except for employing 93.8 g (0.50 mol.) of 5-methoxythiosalicylic acid in place of thiosalicylic acid, to obtain 137.3 g (0.45 mol.) of 2-nitro-2'-carboxy-4'-methoxy-diphenylsulfide. The yield from 5-methoxythiosalicylic acid was 90%. Melting point: 185-187°C.

[Example 5]

The procedures of Example 1 were repeated except for employing methanol in place of N,N-dimethylformamide, to obtain 131.3 g (0.48 mol.) of 2-nitro-2'-carboxy-diphenylsulfide. The yield from thiosalicylic acid was 96%.

[Example 6]

The procedures of Example 5 were repeated except for employing 46.0 g (1.15 mol.) of sodium hydroxide in place of potassium carbonate, to obtain 130.0 g (0.47 mol.) of 2-nitro-2'-carboxy-diphenylsulfide. The yield from thiosalicylic acid was 94%.

[Example 7]

The procedures of Example 5 were repeated except for employing 62.1 g (1.15 mol.) of sodium methylate in place of potassium carbonate and performing the reaction for 5 hours, to obtain 131.8 g (0.48 mol.) of 2-nitro-2'-carboxy-diphenylsulfide. The yield from thiosalicylic acid was 96%.

[Example 8]

The procedures of Example 7 were repeated except for adding 3.9 g (0.02 mol.) of potassium iodide to the reaction mixture in advance of the reaction, to obtain 133.8 g (0.49 mol.) of 2-nitro-2'-carboxy-diphenylsulfide. The yield from thiosalicylic acid was 97%.

[Example 9]

In a 300 mL-volume autoclave were placed Raney-nickel (50% alloy, Ni content: 4 g), 13.8 g (0.05 mol.) of 2-nitro-2'-carboxy-diphenylsulfide obtained in Example 1, and 100 mL of methanol. The mixture was stirred at room temperature for 5 hours at a hydrogen gas pressure of 20 atm. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain 11.3 g (0.046 mol.) of 2-amino-2'-carboxy-diphenylsulfide as a colorless powdery product. The yield from 2-nitro-2'-carboxy-diphenylsulfide was 92%.

$^1\text{H-NMR}$ (DMSO-d_6): δ

5.0-5.9 (br, 2H), 6.5-8.1 (m, 8H), 12.8-13.5 (br, 1H)

[Example 10]

In 50 mL of n-butanol were suspended Raney-nickel (50% alloy, Ni content: 1 g) and 4.0 g (14.5 mmol.) of 2-nitro-2'-carboxy-diphenylsulfide obtained in Example 1. The obtained n-butanol suspension was stirred at 100°C for 15 hours under blowing hydrogen. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give 3.24 g (13.2 mmol.) of 2-amino-2'-carboxy-diphenylsulfide as a colorless powdery product. The yield from 2-nitro-2'-carboxy-diphenylsulfide was 91%.

[Example 11]

In 40 mL of conc. aqueous ammonia solution (ammonia concentration: 28 wt.%) was dissolved 2.75 g (10.0 mmol.) of 2-nitro-2'-carboxy-diphenylsulfide obtained in Example 1. To the resulting aqueous ammonia mixture was dropwise added a solution of 21.6 g (77.8 mmol.) of ferrous sulfate 7 hydrates in 70 mL of water. The resulting mixture was heated at 80°C for 10 minutes for carrying out the reaction. The reaction mixture was cooled to room tem-

perature and filtered. The filtrate was concentrated to 30 mL under reduced pressure, and to the concentrate were added 70 mL of ethyl acetate and 2 mL of acetic acid. The separated organic portion was dried over magnesium sulfate anhydride and filtered to separate the drying agent. The filtrate was concentrated under reduced pressure to give 2.33 g (9.50 mmol.) of 2-amino-2'-carboxy-diphenylsulfide as a colorless powdery product. The yield from 2-nitro-2'-carboxy-diphenylsulfide was 95%.

[Example 12]

The procedures of Example 10 were repeated except for employing 15.2 g (0.05 mol.) of 2-nitro-2'-carboxy-4'-methoxy-diphenylsulfide to obtain 12.7 g (0.046 mol.) of 2-amino-2'-carboxy-4'-methoxy-diphenylsulfide as a colorless powdery product. The yield from 2-nitro-2'-carboxy-4'-methoxy-diphenylsulfide was 92%. Melting point: 150-151°C.

[Example 13]

In a 300 mL-volume autoclave were placed 1.37 g of Pd(5 wt.)/C, 13.7 g (0.05 mol.) of 2-nitro-2'-carboxy-diphenylsulfide obtained in Example 1, and 95 mL of methanol. The mixture was stirred at 25°C for 6 hours at a hydrogen gas pressure of 10 atm., for performing hydrogenation reaction. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure, to obtain 11.7 g (0.048 mol.) of 2-amino-2'-carboxy-diphenylsulfide as a colorless powdery product. The yield from 2-nitro-2'-carboxy-diphenylsulfide was 95%. Melting point: 150-151°C.

[Example 14]

The procedures of Example 13 were repeated except for changing the reaction temperature and period into 50°C and 4 hours, respectively, to obtain 12.0 g (0.049 mol.)

of 2-amino-2'-carboxy-diphenylsulfide. The yield from 2-nitro-2'-carboxy-diphenylsulfide was 98%.

[Example 15]

5 The procedures of Example 14 were repeated except for utilizing 2.91 g of Pd(5 wt.)/C(water content: 52.9 wt.%) in place of 1.37 g of Pd(5 wt.)/C, to obtain 11.9 g (0.049 mol.) of 2-amino-2'-carboxy-diphenylsulfide. The yield from 2-nitro-2'-carboxy-diphenylsulfide was
10 97%.

[Example 16]

The procedures of Example 14 were repeated except for changing the amount of methanol and the reaction
15 period into 50 mL and 6 hours, to obtain 11.9 g (0.049 mol.) of 2-amino-2'-carboxy-diphenylsulfide. The yield from 2-nitro-2'-carboxy-diphenylsulfide was 97%.

[Example 17]

20 The procedures of Example 14 were repeated except for changing the amount of methanol and the reaction period into 180 mL and 6 hours, to obtain 11.2 g (0.046 mol.) of 2-amino-2'-carboxy-diphenylsulfide. The yield from 2-nitro-2'-carboxy-diphenylsulfide was 91%.

25

[Example 18]

The procedures of Example 14 were repeated except for replacing methanol with ethanol, to obtain 11.2 g (0.046 mol.) of 2-amino-2'-carboxy-diphenylsulfide. The
30 yield from 2-nitro-2'-carboxy-diphenylsulfide was 92%.

[Example 19]

The procedures of Example 14 were repeated except for utilizing 640 mg of platinum oxide (PtO₂) in place of
35 1.37 g of Pd(5 wt.)/C, to obtain 10.8 g (0.044 mol.) of 2-amino-2'-carboxy-diphenylsulfide. The yield from 2-

nitro-2'-carboxy-diphenylsulfide was 88%.

[Example 20]

The procedures of Example 14 were repeated except for employing 15.2 g (0.05 mol.) of 2-nitro-2'-carboxy-4'-methoxy-diphenylsulfide obtained in Example 4, to obtain 12.7 g (0.046 mol.) of 2-amino-2'-carboxy-4'-dimethoxy-diphenylsulfide. The yield from 2-nitro-2'-carboxy-4'-dimethoxy-diphenylsulfide was 92%.

[Example 21]

In 300 mL of toluene was dissolved 24.5 g (0.10 mol.) of 2-amino-2'-carboxy-diphenylsulfide. The resulting toluene solution was refluxed for 20 hours for performing the reaction. The reaction mixture was cooled to room temperature, and the precipitated crystalline product was collected by filtration. The collected product was dried to obtain 15.7 g (0.069 mol.) of dibenzo[b,f]-[1,4]thiazepin-11-one in the form of colorless needles. The yield from 2-amino-2'-carboxy-diphenylsulfide was 69%. Melting point: 259-260°C.

$^1\text{H-NMR}$ (DMSO-d_6): δ

7.05-7.80 (m, 8H), 10.7 (s, 1H)

[Example 22]

In 300 mL of toluene was dissolved 24.5 g (0.10 mol.) of 2-amino-2'-carboxy-diphenylsulfide. The resulting toluene solution was refluxed in a Dean-Stark apparatus for 20 hours with azeotropic dehydration for performing the reaction. The reaction mixture was cooled to room temperature, and the precipitated crystalline product was collected by filtration. The collected product was dried to obtain 18.2 g (0.080 mol.) of dibenzo[b,f]-[1,4]thiazepin-11-one in the form of colorless needles. The yield from 2-amino-2'-carboxy-diphenylsulfide was 80%.

[Example 23]

The procedures of Example 22 were repeated except for employing xylene as the reaction solvent and 15 hours as the reaction period, to obtain 22.3 g (0.098 mol.) of dibenzo[b,f] [1,4]thiazepin-11-one in the form of colorless needles. The yield from 2-amino-2'-carboxy-diphenylsulfide was 98%.

[Example 24]

The procedures of Example 22 were repeated except for employing cumene as the reaction solvent and 10 hours as the reaction period, to obtain 22.3 g (0.098 mol.) of dibenzo[b,f] [1,4]thiazepin-11-one in the form of colorless needles. The yield from 2-amino-2'-carboxy-diphenylsulfide was 98%.

[Example 25]

In 300 mL of xylene was dissolved 24.5 g (0.10 mol.) of 2-amino-2'-carboxy-diphenylsulfide obtained in Example 14. The resulting xylene solution was refluxed in a Dean-Stark apparatus for 15 hours with azeotropic dehydration for performing the reaction. The reaction mixture was cooled to 75°C. The cooled reaction mixture was stirred at 75°C for 30 minutes after addition of 240 mL of an aqueous saturated sodium hydrogen carbonate solution. The precipitated crystalline product was then collected by filtration. The collected product was dried to obtain 21.5 g (0.095 mol.) of dibenzo[b,f] [1,4]thiazepin-11-one in the form of colorless needles. The yield from 2-amino-2'-carboxy-diphenylsulfide was 95%.

[Example 26]

The procedures of Example 25 were repeated except for employing 200 mL of an aqueous 1N sodium hydroxide solution in place of the aqueous saturated sodium hydrogen carbonate solution, to obtain 21.1 g (0.093 mol.) of

dibenzo[b,f][1,4]thiazepin-11-one in the form of colorless needles. The yield from 2-amino-2'-carboxy-diphenylsulfide was 93%.

5 [Example 27]

The procedure of Example 25 were repeated except for employing cumene as reaction solvent and 10 hours as reaction period to obtain 22.0 g (0.097 mol.) of dibenzo-
10 [b,f][1,4]thiazepin-11-one in the form of colorless needles. The yield from 2-amino-2'-carboxy-diphenylsulfide: 97%.

[Example 28]


The procedures of Example 23 were repeated except
15 for employing 27.5 g (0.10 mol.) of 2-amino-2'-carboxy-4'-methoxy-diphenylsulfide obtained in Example 12, to obtain 23.6 g (0.092 mol.) of 2-methoxy-dibenzo[b,f][1,4]-thiazepin-11-one in the form of colorless needles. The
20 yield from 2-amino-4-methoxy-2'-carboxy-diphenylsulfide was 92%. Melting point: 220-223°C.

[Industrial Utilization]

A dibenzothiazepine derivative represented by the formula (5) and of value as an intermediate compound for
25 preparing pharmaceuticals can be easily produced at high yield with easy procedures according to the process for preparing a dibenzothiazepine derivative of the present invention, which comprises the steps of reacting a nitrobenzene derivative with a thiosalicylic acid derivative
30 to produce a 2-nitro-2'-carboxy-diphenylsulfide derivative, reducing the product to produce a 2-amino-2'-carboxy-diphenylsulfide derivative, and subjecting the product to dehydration-condensation reaction.

WHAT IS CLAIMED IS:


1. A process for preparing a dibenzothiazepine derivative of the following formula (5):




in which each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ independently represents a hydrogen atom, an alkyl group, an alkoxy group, an alkylcarbonyl group, an aryl group, an aryloxy group, or an arylcarbonyl group, each group being optionally substituted,

which comprises the steps of:


reacting a nitrobenzene derivative of the following formula (1):



in which each of R¹, R², R³ and R⁴ has the meaning as described above, and X represents a halogen atom, with a thiosalicylic acid derivative of the following formula (2):




in which each of R⁵, R⁶, R⁷ and R⁸ has the meaning as described above,
to obtain a 2-nitro-2'-carboxy-diphenylsulfide derivative of the following formula (3):



in which each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ has the meaning as described above;

reducing the obtained 2-nitro-2'-carboxy-diphenylsulfide derivative, to obtain a 2-amino-2'-carboxy-diphenylsulfide derivative of the following formula (4):



25 in which each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ has the meaning as described above;

and

subjecting the obtained 2-amino-2'-carboxy-diphenylsulfide derivative to dehydration-condensation reaction.

30


2. The process for the preparation of the dibenzothiazepine derivative as defined in claim 1, wherein the reaction between the nitrobenzene derivative of the formula (1) and the thiosalicylic acid derivative of the formula (2) is performed in an organic solvent in the presence of a base.

35

3. The process for the preparation of the dibenzothiazepine derivative as defined in claim 1, wherein the reduction of the 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3) is performed in the presence of a compound selected from the group consisting of Raney-nickel, a ferrous salt, palladium, platinum, a palladium compound and a platinum compound.


4. The process for the preparation of the dibenzothiazepine derivative as defined in claim 1, wherein the dehydration-condensation reaction of the 2-amino-2'-carboxy-diphenylsulfide derivative of the formula (4) is performed in an organic solvent.

5. A process for preparing a dibenzothiazepine derivative of the following formula (5):




in which each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ independently represents a hydrogen atom, an alkyl group, an alkoxy group, an alkylcarbonyl group, an aryl group, an aryloxy group, or an arylcarbonyl group, each group being optionally substituted, which comprises the steps of:

reducing a 2-nitro-2'-carboxy-diphenylsulfide derivative of the following formula (3):



in which each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ has the meaning as described above, to obtain a 2-amino-2'-carboxy-diphenylsulfide derivative of the following formula (4):



in which each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ has the meaning as described above;

15 and


subjecting the obtained 2-amino-2'-carboxy-diphenylsulfide derivative to dehydration-condensation reaction.

20 6. The process for the preparation of the dibenzothiazepine derivative as defined in claim 5, wherein the reduction of the 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3) is performed in the presence of a compound selected from the group consisting of Raney-nickel, a ferrous salt, palladium, platinum, a pal-

25 ladium compound and a platinum compound.

30 7. The process for the preparation of the dibenzothiazepine derivative as defined in claim 5, wherein the dehydration-condensation reaction of the 2-amino-2'-carboxy-diphenylsulfide derivative of the formula (4) is performed in an organic solvent.

8. A 2-nitro-2'-carboxy-diphenylsulfide derivative of the formula (3):



5
10 in which each of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 independently represents a hydrogen atom, an alkyl group, an alkoxy group, an alkylcarbonyl group, an aryl group, an aryloxy group, or an arylcarbonyl group, each group being optionally substituted.

205070-1520E001

Declaration and Power of Attorney For Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者であると（下記の名称が複数の場合）信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PROCESS FOR PREPARING DIBENZOTHAZEPINE

DERIVATIVES

上記発明の明細書（下記の欄で×印がついていない場合は、本書に添付）は、

The specification of which is attached hereto unless the following box is checked:

☐ __月__日に提出され、米国出願番号または特許協定条約国際出願番号を____とし、
（該当する場合）____に訂正されました。

☐ was filed on July 9, 1999
as United States Application Number or
PCT International Application Number
PCT/JP99/03719 and was amended on
____ (if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第 37 編第 1 条 56 項に定義されたとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

10030251-010902

Japanese Language Declaration

(日本語宣言書)

私は、米国法典第 35 編 119 条(a)-(d)項又は 365 条(b)項に基づき下記の、米国以外の国の少なくとも一方国を指定している特許協力条約 365(a)項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

I hereby claim foreign priority under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

外国での先行出願

Priority Not Claimed

優先権主張なし

10-015022	Japan	09/01/1998	<input checked="" type="checkbox"/>
(Number) (番号)	(Country) (国名)	(Day/Month/Year Filed) (出願年月日)	
			<input type="checkbox"/>
(Number) (番号)	(Country) (国名)	(Day/Month/Year Filed) (出願年月日)	
			<input type="checkbox"/>
(Number) (番号)	(Country) (国名)	(Day/Month/Year Filed) (出願年月日)	

私は、第 35 編米国法典 119 条(e)項に基づいて下記の米国特許出願規定に記載された権利をここに主張いたします。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.) (出願番号)	(Filing Date) (出願日)	(Application No.) (出願番号)	(Filing Date) (出願日)
-----------------------------	------------------------	-----------------------------	------------------------

私は、下記の米国法典第 35 編 120 条に基づいて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約 365 条(c)に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第 35 編 112 条第 1 項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規制法典第 37 編 1 条 56 項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況: 特許許可済、継続中、放棄済)
-----------------------------	------------------------	---

20060707 15200007

(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況: 特許許可済、継続中、放棄済)
(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況: 特許許可済、継続中、放棄済)
(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況: 特許許可済、継続中、放棄済)
(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況: 特許許可済、継続中、放棄済)
(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況: 特許許可済、継続中、放棄済)
(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況: 特許許可済、継続中、放棄済)
(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況: 特許許可済、継続中、放棄済)

私は、私自身の知識に基づいて本宣言書中で私が行う表明が真実であり、かつ私の入手した情報と私の信じていることに基く表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第 18 編第 1001 条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の声明を行えば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

10030251.010902

Japanese Language Declaration
(日本語宣言書)

委任状: 私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁護士または代理人として、下記の者を指名いたします。(弁護士、または代理人の氏名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith (list name and registration number).

Daniel W. Sixbey, (Reg. No. 20,932)
Charles M. Leedom, Jr. (Reg. No. 26,477)
David S. Safran (Reg. No. 27,997)
Donald R. Studebaker (Reg. No. 32,815)
Tim L. Brackett (Reg. No. 36,092)
Robert M. Schulman (Reg. No. 31,196)

Thomas W. Cole (Reg. No. 28,290)
Jeffrey L. Costellia (Reg. No. 35,483)
Eric J. Robinson (Reg. No. 38,285)
Stuart J. Friedman (Reg. No. 24,312)
Daniel S. Song (Reg. No. 43,143)

ここに署名する者は、この申請に関して米特許商標局においてなされるべき如何なる行動に関しても、ここに指名された米国弁護士または代理人が、米国弁護士または代理人とここに署名した者との間で直接の連絡を取ることにし、
からの指示を受け入れてそれに従う権限を与える。指示を出す人物に変更がある場合は、ここに指名された米国弁護士または代理人は、ここに署名した者からその旨通知を受ける。

The undersigned hereby authorizes any U. S. attorney or agent named herein to accept and follow instructions from Nixon Peabody LLP as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U. S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U. S. attorneys or agents named herein will be so notified by the undersigned.

書類送付先

Send Correspondence to:

Thomas W. Cole
Nixon Peabody LLP
8180 Greensboro Dr., Suite 800
McLean, VA 22102

直接電話連絡先: (名前及び電話番号)

Direct Telephone Calls to: (name and telephone number)

唯一または第一発明者名	1-00	Full name of sole or first inventor
発明者の署名	日付	Inventor's signature Date
住所		Residence
国籍		Citizenship
私書箱		Post Office Address

Kogushi, Ube-shi, Yamaguchi, 755-0067
Japan

第二共同発明者名	2-00	Full name of second joint inventor, if any <u>Shigeyoshi Nishino</u>	
第二共同発明者の署名	日付	Second inventor's signature <u>Shigeyoshi Nishino</u>	Date 26/12/2001
住所	Residence <u>Yamaguchi, Japan JPX</u>		
国籍	Citizenship Japan		
私書箱	Post Office Address c/o Ube Laboratories, Ube Industries, Ltd., 1978-5, O-Aza		

Kogushi, Ube-shi, Yamaguchi, 755-0067, Japan

第三共同発明者名	3-00	Full name of third joint inventor, if any <u>Kiyotaka Yoshii</u>	
第三共同発明者の署名	日付	Third inventor's signature <u>Kiyotaka Yoshii</u>	Date 26/12/2001
住所	Residence <u>Yamaguchi, Japan JPX</u>		
国籍	Citizenship Japan		
私書箱	Post Office Address c/o Ube Laboratories, Ube Industries, Ltd., 1978-5, O-Aza		

Kogushi, Ube-shi, Yamaguchi, 755-0067, Japan

第四共同発明者名	Full name of fourth joint inventor, if any		
第四共同発明者の署名	日付	Fourth inventor's signature	Date
住所	Residence		
国籍	Citizenship		
私書箱	Post Office Address		

20060707 10:00:00